Plain-English translation of NCT05977036 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This trial is testing whether a blood test called DiviTum can help doctors make faster decisions about your breast cancer treatment. You'll receive standard first-line treatment (a hormone therapy plus a CDK4/6 inhibitor, preferably ribociclib) and have blood drawn at specific timepoints to measure how well the medication is working. If the blood test shows your treatment isn't working well early on, your doctor may recommend switching to a different therapy.
Currently, doctors wait weeks or months for imaging scans to see if breast cancer treatments are working. This trial aims to use a blood test to spot treatment failure much earlier, so patients who aren't benefiting can switch to other options sooner and potentially live longer without their cancer getting worse.
You likely qualify if…
You likely don't qualify if…
You will visit the clinic at baseline, around week 2, and at several follow-up timepoints to have blood drawn for the blood test and to receive your medication. If your blood test results show the treatment is working well, you'll continue on the same medication and may have imaging scans stretched out from every 3 months to every 6 months. If the blood test suggests the treatment isn't working, your doctor will recommend switching to an alternative therapy. You'll be monitored closely until your cancer shows signs of progression.
AI-generated summary from trial data · Jun 3, 2026 · Not medical advice
United States